ESPR
Esperion Therapeutics Inc
3.20$
+0.0%
vs. previous close
Closing price · As of: Jul 15, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +31.7% | -5.1% | +327.1% | -46.4% | -30.1% | +33.9% | -6.0% | +26.8% | +6.0% | +92.9% | -52.4% | – | |
| – | +97.1% | -14.4% | -12.0% | +54.9% | +10.7% | +48.3% | +23.0% | -9.5% | +94.2% | -49.7% | +24.1% | – | |
| – | +8.4% | +1.0% | +513.8% | -54.4% | -41.0% | +26.6% | -23.1% | +60.9% | -40.8% | +340.9% | -67.6% | – | |
| – | -32.6% | +19.2% | -24.5% | -14.5% | -9.3% | +5.6% | +14.4% | -42.4% | +95.2% | -1.5% | -35.5% | – | |
| – | -18.4% | -10.3% | +40.8% | +5.2% | -9.5% | -71.4% | +276.3% | -8.1% | +5.9% | -1.0% | +4.1% | – | |
| – | -14.2% | +31.3% | -12.3% | +0.5% | -9.5% | -4.9% | +16.0% | -15.9% | -10.5% | +32.3% | -5.9% | – | |
| – | – | – | – | -96.4% | -721.4% | – | – | – | -240.4% | – | -107.7% | – | |
| – | +3.2% | +0.4% | -6.9% | -2.1% | +9.9% | +8.9% | +18.3% | +5.4% | +7.6% | +2.7% | -12.5% | – | |
| – | – | – | – | -201.5% | – | – | – | – | – | – | -139.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | -201.5% | – | – | – | – | – | – | -140.7% | – | |
| – | – | – | – | -164.2% | – | – | – | – | -218.8% | – | -152.1% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: July 15, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.